<VariationArchive VariationID="695019" VariationName="NM_000156.6(GAMT):c.145del (p.Tyr49fs)" VariationType="Deletion" Accession="VCV000695019" Version="6" RecordType="classified" NumberOfSubmissions="5" NumberOfSubmitters="5" DateLastUpdated="2024-06-23" DateCreated="2019-12-17" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="683148" VariationID="695019">
      <GeneList>
        <Gene Symbol="LOC130062945" FullName="ATAC-STARR-seq lymphoblastoid silent region 9707" GeneID="130062945" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>19p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1401280" stop="1401859" display_start="1401280" display_stop="1401859" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="GAMT" FullName="guanidinoacetate N-methyltransferase" GeneID="2593" HGNC_ID="HGNC:4136" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>19p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1397026" stop="1401542" display_start="1397026" display_stop="1401542" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1397024" stop="1401568" display_start="1397024" display_stop="1401568" Strand="-" />
          </Location>
          <OMIM>601240</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000156.6(GAMT):c.145del (p.Tyr49fs)</Name>
      <CanonicalSPDI>NC_000019.10:1401331:A:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1401332" stop="1401332" display_start="1401332" display_stop="1401332" variantLength="1" positionVCF="1401331" referenceAlleleVCF="TA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1401331" stop="1401331" display_start="1401331" display_stop="1401331" variantLength="1" positionVCF="1401330" referenceAlleleVCF="TA" alternateAlleleVCF="T" />
      </Location>
      <OtherNameList>
        <Name>NM_000156.6(GAMT):c.145del</Name>
        <Name>p.Tyr49fs</Name>
      </OtherNameList>
      <ProteinChange>Y49fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.1401332del" Assembly="GRCh38">
            <Expression>NC_000019.10:g.1401332del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.1401331del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.1401331del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009785.1" sequenceAccession="NG_009785" sequenceVersion="1" change="g.5222del">
            <Expression>NG_009785.1:g.5222del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000156.6" sequenceAccession="NM_000156" sequenceVersion="6" change="c.145del" MANESelect="true">
            <Expression>NM_000156.6:c.145del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000147.1" sequenceAccession="NP_000147" sequenceVersion="1" change="p.Tyr49fs">
            <Expression>NP_000147.1:p.Tyr49fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_138924.3" sequenceAccession="NM_138924" sequenceVersion="3" change="c.145del">
            <Expression>NM_138924.3:c.145del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_620279.1" sequenceAccession="NP_620279" sequenceVersion="1" change="p.Tyr49fs">
            <Expression>NP_620279.1:p.Tyr49fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000156.5" sequenceAccession="NM_000156" sequenceVersion="5" change="c.145delT">
            <Expression>NM_000156.5:c.145delT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1384688313" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00001" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000156.6(GAMT):c.145del (p.Tyr49fs) AND Deficiency of guanidinoacetate methyltransferase" Accession="RCV000857223" Version="5">
        <ClassifiedConditionList TraitSetID="2278">
          <ClassifiedCondition DB="MedGen" ID="C0574080">Deficiency of guanidinoacetate methyltransferase</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2023-09-14" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000156.6(GAMT):c.145del (p.Tyr49fs) AND Cerebral creatine deficiency syndrome" Accession="RCV001766770" Version="4">
        <ClassifiedConditionList TraitSetID="16862">
          <ClassifiedCondition DB="MedGen" ID="C5244016">Cerebral creatine deficiency syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-11-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-09-14" NumberOfSubmissions="5" NumberOfSubmitters="5" DateCreated="2019-12-17" MostRecentSubmission="2024-06-17">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">21140503</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/7aa4c0b5-0a11-4732-8122-cb6094f65f10</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="2278" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2252" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CEREBRAL CREATINE DEFICIENCY SYNDROME 2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0005" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Deficiency of guanidinoacetate methyltransferase</ElementValue>
                <XRef ID="Guanidinoacetate+Methyltransferase+Deficiency/3202" DB="Genetic Alliance" />
                <XRef ID="124239003" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCDS2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2578" />
                <XRef ID="2578" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Guanidinoacetate, Guanidinoacetate Methyltransferase Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Algorithm, GAMT Deficiency: Elevated Guanidinoacetate, 2022</CitationText>
              </Citation>
              <XRef ID="382" DB="Orphanet" />
              <XRef ID="C0574080" DB="MedGen" />
              <XRef ID="MONDO:0012999" DB="MONDO" />
              <XRef Type="MIM" ID="612736" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="16862" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="16661" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cerebral creatine deficiency syndrome</ElementValue>
                <XRef ID="MONDO:0000456" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Creatine deficiency syndromes</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCAD</ElementValue>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CDS</ElementValue>
                <XRef ID="79172" DB="Orphanet" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18952" />
                <XRef ID="18952" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <XRef ID="79172" DB="Orphanet" />
              <XRef ID="C5244016" DB="MedGen" />
              <XRef ID="MONDO:0000456" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1964587" SubmissionDate="2019-07-05" DateLastUpdated="2019-12-17" DateCreated="2019-12-17">
        <ClinVarSubmissionID localKey="5_July 2019|Orphanet:382" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000999807" DateUpdated="2019-12-17" DateCreated="2019-12-17" Type="SCV" Version="1" SubmitterName="Center of Genomic medicine, Geneva, University Hospital of Geneva" OrgID="505593" OrganizationCategory="laboratory" OrgAbbreviation="GenMed_GVA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-12-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant was identified in composite heterozygosity with another variant in the same gene in a female patient with IDD. The unaffected parents are both carriers of one of the two variants in the same gene, while the affected brother also harbours both variants in composite heterozygosity</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>paternal</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">10</Age>
              <Age Type="maximum" age_unit="years">19</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.(Tyr49Ilefs*65)</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.5:c.145del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Deficiency of guanidinoacetate methyltransferase</ElementValue>
            </Name>
            <XRef DB="Orphanet" ID="ORPHA382" />
          </Trait>
        </TraitSet>
        <Citation Abbrev="ACMG, 2015" Type="practice guideline">
          <ID Source="PubMed">25741868</ID>
          <ID Source="DOI">10.1038/gim.2015.30</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB5917030</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2645038" SubmissionDate="2020-04-29" DateLastUpdated="2020-06-18" DateCreated="2020-06-18">
        <ClinVarSubmissionID localKey="NM_000156.5:c.145delT|MedGen:C0574080" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001337768" DateUpdated="2020-06-18" DateCreated="2020-06-18" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-01-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21140503</ID>
          </Citation>
          <Comment>Variant summary: GAMT c.145delT (p.Tyr49IlefsX65) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 6.2e-06 in 162428 control chromosomes. c.145delT has been reported in the literature in at least one individual affected with Guanidinoactetate methyltransferase deficiency (Alcaide_2011). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in &lt;10% of normal activity (Alcaide_2011). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.5:c.145delT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Deficiency of guanidinoacetate methyltransferase</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0574080" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7346641</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3896969" SubmissionDate="2021-11-02" DateLastUpdated="2022-02-01" DateCreated="2021-11-06">
        <ClinVarSubmissionID localKey="432edfa6-61f5-46cb-a74c-4540c2896beb" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001999930" DateUpdated="2022-02-01" DateCreated="2021-11-06" Type="SCV" Version="2" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.145del variant in GAMT has been reported in 1 individual, in the homozygous state, with cerebral creatine deficiency syndrome (PMID: 19892372) and has been identified in 0.004% (1/26808) of Latino/Admixed American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs1384688313). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID#: 695019) and has been interpreted as pathogenic by Integrated Genetics (Laboratory Corporation of America) and Center of Genomic medicine (Geneva, University Hospital of Geneva). In vitro functional studies provide evidence that the c.145del variant impacts protein function (PMID: 21140503). However, these types of assays may not accurately represent biological function. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 49 and leads to a premature termination codon 16 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the GAMT gene is an established disease mechanism in autosomal recessive cerebral creatine deficiency syndrome. The phenotype of an individual homozygous for this variant is highly specific for cerebral creatine deficiency syndrome based on strict biochemical investigations consistent with disease (PMID: 21140503). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive cerebral creatine deficiency syndrome. ACMG/AMP Criteria applied: PM3_supporting, PVS1, PS3, PP4, PM2_supporting (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Abbrev="ACMG, 2015" Type="practice guideline">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000156.6(GAMT):c.145del</Name>
            <Name>p.Tyr49fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.10:g.1401332del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0000456" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10607670</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="7900753" SubmissionDate="2024-01-04" DateLastUpdated="2024-01-06" DateCreated="2024-01-06">
        <ClinVarSubmissionID localKey="7aa4c0b5-0a11-4732-8122-cb6094f65f10" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004227929" DateUpdated="2024-01-06" DateCreated="2024-01-06" Type="SCV" Version="1" SubmitterName="ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen" OrgID="508816" OrganizationCategory="consortium" OrgAbbreviation="ClinGen CCDS VCEP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-14">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/7aa4c0b5-0a11-4732-8122-cb6094f65f10</URL>
          </Citation>
          <Comment>The NM_000156.6:c.145del (p.Tyr49Ilefs*65) variant in GAMT is a frameshift variant that is predicted to cause a premature stop codon in biologically-relevant-exon 3/6, leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). A Spanish patient, who is homozygous for the variant, has been reported with clinical symptoms consistent with GAMT deficiency, elevated guanidinoacetate in urine and plasma, and deficient GAMT activity in fibroblasts (PMID: 19892372, 21140503) (PP4_Strong, PM3_Supporting). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0000373 (1/26808 alleles) in the Lation/Admixed American population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (&lt;0.0004), meeting this criterion (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 695019). In summary, this variant meets the criteria to be classified as pathogenic for GAMT deficiency. GAMT-specific ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (CCDS VCEP) (Specifications Version 1.1.0): PVS1, PP4_Strong, PM2_Supporting, PM3_Supporting. (Classification approved by the ClinGen CCDS VCEP on Sept. 14, 2023)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ClinGen_CCDS_ACMG_Specifications_GAMT_v1.1</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/8u1i2ttx/clingen_ccds_acmg_specifications_gamt_v1.1.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000156.6(GAMT):c.145del</Name>
            <Name>p.Tyr49fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.10:g.1401332del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0012999" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14134802</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9818953" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2024-06-17">
        <ClinVarSubmissionID localKey="NM_000156.6:c.145del|OMIM:612736" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005058879" DateUpdated="2024-06-17" DateCreated="2024-06-17" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.6:c.145del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612736" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3896969" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0000456" MappingRef="MONDO">
        <MedGen CUI="C5244016" Name="Cerebral creatine deficiency syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2645038" TraitType="Disease" MappingType="Name" MappingValue="Deficiency of guanidinoacetate methyltransferase" MappingRef="Preferred">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9818953" TraitType="Disease" MappingType="XRef" MappingValue="612736" MappingRef="OMIM">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1964587" TraitType="Disease" MappingType="Name" MappingValue="Deficiency of guanidinoacetate methyltransferase" MappingRef="Preferred">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7900753" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0012999" MappingRef="MONDO">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

